Aera Therapeutics

Biotech · Private

Protein nanoparticle delivery platform for genetic payload transport to multiple organs

aeratx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
23
0 granted · 23 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1639Rapt Therapeutics—$303M
1640SAPPHIRE BIOTECH, INC.——
1641Atalanta Therapeutics——
1642Aera Therapeutics——
1643LIGANDOMICSRX, LLC——
1644DOPHEN BIOMED, INC.——
1645T3S Technologies, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 23
  • Arc-based Capsids And Uses Thereofapplication
  • Modified CAS9-IID Nucleases And Uses Thereofapplication
  • Modified Iscb Nucleases, Modified Guide Rnas, And Uses Thereofapplication
  • Chimeric Antigen Receptor Constructsapplication
  • Process For Preparation Of Targeted Lipid Nanoparticlesapplication
  • Non-enveloped Capsid Delivery Systems And Uses Thereofapplication
  • Delivery Compositionsapplication
  • Poly(a) Tails For Mrna And Non-coding Rna, And Uses Thereofapplication
  • Engineered Mobile Genetic Element Systemsapplication
  • Delivery Compositionsapplication
  • Capsids With Effector-polypeptide Conjugates And Uses Thereofapplication
  • Chimeric Antigen Receptor Constructsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.